At Travere Therapeutics, we are committed to supporting independent educational activities that increase understanding of how to improve the care of patients with rare disease

Travere may support medical education grant applications for independent education designed to close knowledge gaps identified in the healthcare landscape, drive measurable improvements in knowledge and performance of healthcare professionals, and advance patient health outcomes.

“Independent” means that the projects funded by the companies are the full responsibility of the recipient organization. Travere does not have influence over any aspect of the supported projects and only ask for interim and final outcomes reports including a description of the impact of the projects. The program must be of high quality, unbiased, innovative, and evidence based. Travere may provide medical education grants to support independent programs for healthcare professionals, patients, consumers, and healthcare associations, foundations and institutions, in which the programs relate to our therapies and therapeutic focus.


Educational providers and the activities they develop must be compliant with all applicable legal and regulatory guidelines, and the ethical standards under which Travere conducts business. A medical education grant application must be compliant with the current guidelines including AMA Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the ACCME Standards for Commercial Support, the US Food and Drug Administration’s December 3, 1997 Final Guidance for Industry Supported Scientific and Educational activities, the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and the PhRMA Code of Interactions with HealthCare Professionals.

Our medical education grant areas of interest

Educate healthcare professionals to create awareness of:

  1. The benefits of early diagnosis and aggressive intervention aimed at lowering proteinuria and preserving kidney function in people living with IgA nephropathy (IgAN).
  2. The dual roles of endothelin-1 and angiotensin II as potent proliferative, proinflammatory, profibrotic, vasoactive, and tissue damaging drivers of glomerular injury.
  3. The evolving treatment landscape in IgAN, including:
    • The importance of treating beyond ‘standard of care’ with the proactive and combined use of new and emerging therapies.
    • The safe and effective use of sparsentan, a unique dual-acting molecule, as foundational therapy alone or in combination with other agents.


Travere Therapeutics may support the following types of medical educational grants:

  • Medical educational grants can be certified educational programs (CME/CE)
  • Activities for non-accredited education of healthcare professionals or patients, and strictly for educational purposes


Grants Portal

Any personal data you provide Travere Therapeutics will be processed according to our Privacy Policies.